This site is intended for US Healthcare Professionals only.
To report an adverse reaction or product complaint, call 1-888-BLUPRNT, option 2, or visit or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Search Medical Information

Medical information from Blueprint Medicines

Search for medical information on our approved products and investigational compounds

Select a Medicine or Compound
  • Avapritinib

Blueprint Medicines is a global precision therapy company that aims to invent life-changing medicines for people with cancer and hematologic disorders.

This scientific information is being provided as a non-promotional educational resource for healthcare providers in response to an unsolicited request based on the specific search terms entered. It is not intended to be a substitute for consultation and review of reference materials and medical literature pertaining to individual clinical circumstances. Blueprint Medicines does not provide medical advice. To the extent the materials reference uses not in product labeling, the safety and efficacy of such uses have not been established and are not approved by the US Food and Drug Administration. Please refer to the full Product Label for complete prescribing information.

Medical Resources

Congress Presentations & Publications

Read and download peer-reviewed publications, as well as posters and oral presentations from recent medical congresses.

Early Access Policy

Learn about the criteria to request early access to our investigational medicines outside of clinical trials.

Clinical Trials

Learn more about our clinical trials.

Educational Resources

Access informational resources that may be helpful to your practice.

Contact Blueprint Medicines

Submit a Medical Inquiry Request information about our products.

Contact a Medical Science LiaisonOur representatives are available to help you with your medical inquiries.

Blueprint Medicines is a pharmaceutical company focusing on the research, development, and commercialization of products in oncology, hematology, and rare diseases. This website is for US healthcare professionals for educational purposes only. Scientific information and data may include investigational use(s) of compounds for which efficacy and safety have not been established. Blueprint Medicines does not promote or endorse the use of its products in a manner not consistent with the approved label.

*This tool is designed to assess drug-drug interactions for patients taking avapritinib 25 mg daily. The data are based on internal research. According to the US Prescribing Information for avapritinib, avoid coadministration of avapritinib with a strong or moderate CYP3A inhibitor or inducer.